

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CONCORD HEALTHCARE GROUP CO., LTD.

美中嘉和醫學技術發展集團股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2453)

VOLUNTARY ANNOUNCEMENT OFFICIAL RELEASE OF THE PROTON THERAPY LARGE MODEL

This announcement is made by the board of directors (the “**Board**”) of Concord Healthcare Group Co., Ltd. (the “**Company**”) on a voluntary basis.

The Company has made important progress in precise tumor diagnosis and treatment technology. The Company's self-developed large language model (“**LLM**”) in the vertical field of proton therapy was officially released and successfully deployed in Guangzhou Concord Cancer Hospital. Since the commencement of the proton therapy in Guangzhou Concord Cancer Hospital, the proton therapy has completed a number of high-quality patient treatment cases, demonstrating the outstanding advantages of precise treatment, significant efficacy, and reduced side effects.

The Company's proton LLM is the first LLM focusing on proton therapy in China, and its research and development relies on the tumor diagnosis and treatment technology system and massive data accumulated by the Company over the years. It integrates nearly 10,000 high-quality radiotherapy cases to construct multimodal medical data, and also integrates data from Proton China (《質子中國》) and professional journal literature to achieve enhancement of model training.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Concord Healthcare Group Co., Ltd.
美中嘉和醫學技術發展集團股份有限公司
YANG Jianyu
Chairman and Executive Director

Beijing, the PRC, May 27, 2025

As at the date of this announcement, the Board comprises (i) Dr. YANG Jianyu, Ms. FU Xiao and Mr. CHANG Liang as executive Directors; (ii) Mr. WANG Lei, Mr. SONG Qingbao and Mr. SHI Botao as non-executive Directors; and (iii) Ms. LI Xuemei, Mr. SUN Yansheng and Mr. NG Kwok Yin as independent non-executive Directors.